SCHEMBL16371027

SCHEMBL16371027

CCC1CN(C(C)(C)C)CCC1=O

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28045319 0.81 ALDH1A1 (0.30)
SCHEMBL31363678 0.75 LMNA (0.44) LMNAMAPT
SCHEMBL2569138 0.75 LMNA (0.44) LMNAMAPT
SCHEMBL13389307 0.75 BRD4 (0.31)
SCHEMBL6018336 0.73 LMNA (0.39) LMNAMAPT
SCHEMBL10202863 0.73
SCHEMBL4442111 0.73 LMNA (0.39) LMNAMAPT
SCHEMBL656014 0.69 DDB1 (0.44) MAPT
SCHEMBL17785721 0.69 LMNA (0.36) LMNAMAPT
SCHEMBL6849414 0.68 ESR1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116848114-A Tricyclic derivatives useful as PARP7 inhibitors 北京加科思新药研发有限公司 2023-10-03 CN disclosed
CN-109053742-A New tricyclic compound ABBVIE 公司 2018-12-21 CN disclosed
WO-2015006689-A1 TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION UNIVERSITY OF SOUTH ALABAMA (US) 2015-01-15 WO disclosed